Get the Stockscreener App
4.39
0.69%
0.03
Karyopharm Therapeutics Inc stock is traded at $4.39, with a volume of 33,104.
It is up +0.69% in the last 24 hours and down -10.77% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$4.36
Open:
$4.22
24h Volume:
33,104
Relative Volume:
0.30
Market Cap:
$38.79M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-3.4567
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
-2.23%
1M Performance:
-10.77%
6M Performance:
-58.19%
1Y Performance:
-71.31%
1-Day Range:
$4.22
$4.53
1-Week Range:
$4.19
$4.62
52-Week Range:
$3.51
$17.40
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
4.39 | 38.79M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Two Sigma Investments LP - Defense World
Class Action ReminderNFLX, KPTI & MNKBronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Two Sigma Advisers LP Buys 45,400 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Millennium Management LLC Lowers Stock Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment By Investing.com - Investing.com Nigeria
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment - Investing.com
Karyopharm to Present at the Jefferies Global Healthcare Conference - Kilgore News Herald
Karyopharm to Present at the Jefferies Global Healthcare Conference | KPTI Stock News - GuruFocus
Northern Trust Corp Acquires 54,061 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI Stock News - GuruFocus
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Jane Street Group LLC - Defense World
Karyopharm increases share reserve for equity plan - Investing.com India
Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment - TipRanks
Karyopharm increases share reserve for equity plan By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Sells 817,711 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Hepatic Impairment Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Novartis, ApoPharma, Indivior Inc., Boehringer Ingelheim, Ocera Therapeutics, Orient Europharma, Karyopharm - Barchart.com
Focus Partners Wealth Makes New Investment in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com India
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27% - simplywall.st
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet - simplywall.st
Karyopharm at RBC Capital Markets: Strategic Insights on XPOVIO and Pipeline - Investing.com Australia
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - Eastern Progress
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? - sharewise
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World
Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World
Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus
KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus
Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire
KPTI: RBC Capital Lowers Price Target while Maintaining Outperform Rating | KPTI Stock News - GuruFocus
RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada
KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus
KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus
Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus
KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus
Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus
Karyopharm Therapeutics Inc Reports Q1 2025 Earnings: EPS Loss o - GuruFocus
RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating - marketscreener.com
Barclays Updates Karyopharm (KPTI) Price Target, Eyes Future Dat - GuruFocus
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):